APA (7th ed.) Citation

Imai, H., Wasamoto, S., Tsuda, T., Nagai, Y., Kishikawa, T., Masubuchi, K., . . . Kagamu, H. (2023). Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed. Thoracic Cancer, 14(25), 2567. https://doi.org/10.1111/1759-7714.15036

Chicago Style (17th ed.) Citation

Imai, Hisao, et al. "Using the Neutrophil‐to‐lymphocyte Ratio to Predict the Outcome of Individuals with Nonsquamous Non‐small Cell Lung Cancer Receiving Pembrolizumab Plus Platinum and Pemetrexed." Thoracic Cancer 14, no. 25 (2023): 2567. https://doi.org/10.1111/1759-7714.15036.

MLA (9th ed.) Citation

Imai, Hisao, et al. "Using the Neutrophil‐to‐lymphocyte Ratio to Predict the Outcome of Individuals with Nonsquamous Non‐small Cell Lung Cancer Receiving Pembrolizumab Plus Platinum and Pemetrexed." Thoracic Cancer, vol. 14, no. 25, 2023, p. 2567, https://doi.org/10.1111/1759-7714.15036.